AI assistant
Sending…
C4 Therapeutics, Inc. — Director's Dealing 2022
Jun 14, 2022
33861_dirs_2022-06-14_9352fa4b-37fe-4d9a-92ca-1c3b010cfff7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2022-05-26
Reporting Person: Crystal Adam (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-05-26 | Common Stock | F | 1102 | $7.01 | Disposed | 17648 | Direct |
Footnotes
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person.
More from C4 Therapeutics, Inc.
Board/Management Information
2026
May 15
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Annual Report
2026
Apr 29
Proxy Solicitation & Information Statement
2026
Apr 29
Board/Management Information
2026
Apr 10
Capital/Financing Update
2026
Apr 9
Annual Report
2026
Feb 26
Earnings Release
2026
Feb 26
Director's Dealing
2026
Feb 18